| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/03/2013 | CA2839624A1 Applicator system for applying a viscous liquid to the human skin |
| 01/03/2013 | CA2839608A1 Anti-thrombotic compounds |
| 01/03/2013 | CA2839451A1 Methods and compositions for treatment of cancer and autoimmune disease |
| 01/03/2013 | CA2839398A1 Crystalline form of indazolyl amide derivatives for the treatment glucocorticoid receptor mediated disorders |
| 01/03/2013 | CA2839179A1 A new stable anesthetic composition for reducing skin reactions |
| 01/03/2013 | CA2838976A1 Dha and epa in the reduction of oxidative stress |
| 01/03/2013 | CA2838875A1 Camptothecin derivative, method for preparing same, pharmaceutical composition and use thereof |
| 01/03/2013 | CA2838738A1 Novel crystalline forms of a dipeptidyl peptidase-iv inhibitor |
| 01/03/2013 | CA2838645A1 1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline derivatives |
| 01/03/2013 | CA2838495A1 Substituted cinnamamide derivative, preparation method and use thereof |
| 01/03/2013 | CA2838321A1 Sulphonamide derivatives of alicyclic amines for the treatment of the central nervous system diseases |
| 01/03/2013 | CA2838314A1 Indoleamine derivatives for the treatment of central nervous system diseases |
| 01/03/2013 | CA2838251A1 3,5-diamino-6-chloro-n-(n-(4-(4-(2-(hexyl(2,3,4,5,6-pentahydroxyhexyl)amino)ethoxy)phenyl)butyl) carbamimidoyl)pyrazine-2-carboxamide |
| 01/03/2013 | CA2837453A1 Crystals of glycine derivative and pharmaceutical use thereof |
| 01/03/2013 | CA2834681A1 Stabilized topical formulations containing core-shell microcapsules |
| 01/03/2013 | CA2833824A1 Fluorinated arylalkylaminocarboxamide derivatives |
| 01/03/2013 | CA2833778A1 Compositions and methods for inhibiting gene expression of hepatitis b virus |
| 01/02/2013 | EP2540828A1 Composition comprising inhibitors of IRS-1 and of VEGF |
| 01/02/2013 | EP2540729A1 (7aS, 2'S)-2-Oxoclopidogrel as anti-thrombotic compound |
| 01/02/2013 | EP2540728A1 Heterocyclic compound |
| 01/02/2013 | EP2540725A1 Polymorphs of 1-((4-Methyl-chinazolin-2-yl)methyl)-3-methyl-7-(2-butin-1-yl)-8-(3-(R)-amino-piperidin-1-yl)xanthin |
| 01/02/2013 | EP2540724A1 Hydrochlorides and hydrates of 1-[(3-cyano-pyridin-2-yl) methyl]-3-methyl-7-(2-butin-1-yl)-8-(3-amino-piperidin-1-yl)-xanthi, their manufacture and use of same as medicine |
| 01/02/2013 | EP2540723A1 Spirocycles as inhibitors of 11-beta hydroxyl steroid dehydrogenase type 1 |
| 01/02/2013 | EP2540722A1 Novel anxiolytic compounds |
| 01/02/2013 | EP2540721A1 Ghrelin receptor agonist for treatment of dyscrasia |
| 01/02/2013 | EP2540720A1 1,3,4,8-tetrahydro-2h-pyrido[1,2-a]pyrazine derivative and use of same as hiv integrase inhibitor |
| 01/02/2013 | EP2540711A1 Selenalzole derivative having ligand which activates peroxisome proliferator activated receptor (ppar), preparing method thereof and usage of the chemical compounds |
| 01/02/2013 | EP2540704A2 Benethamine salt forms of atorvastatin |
| 01/02/2013 | EP2540318A1 Sustained-release solid preparation for oral use |
| 01/02/2013 | EP2540317A1 Sustained-release solid preparation for oral use |
| 01/02/2013 | EP2540311A1 Composite body for antigen or drug delivery |
| 01/02/2013 | EP2540307A1 Antibacterial auxiliary agent comprising kombu extract as active ingredient, antibacterial composition, and food or beverage |
| 01/02/2013 | EP2540302A1 Methods and pharmaceutical compositions for healing wounds |
| 01/02/2013 | EP2540301A2 Methods and pharmaceutical compositions for healing wounds |
| 01/02/2013 | EP2540300A1 Epithelial cell-cell adhesion enhancer, and ameliorating, therapeutic or prophylactic agent for allergic diseases using same |
| 01/02/2013 | EP2540299A1 Eye drops for treating eye infection containing levofloxacin, salt thereof or solvate of same, method for treating eye infection, levofloxacin, salt thereof or solvate of same, and utilization thereof |
| 01/02/2013 | EP2540298A1 Coated solid preparation |
| 01/02/2013 | EP2540297A1 Treatment of Cognitive Disorders with (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof |
| 01/02/2013 | EP2540296A1 Arminothiazole derivatives as human stearoyl-coa desaturase inhibitors |
| 01/02/2013 | EP2540295A1 Compositions for the treatment of Fragile X syndrome |
| 01/02/2013 | EP2540294A1 Sustained-release solid preparation for oral use |
| 01/02/2013 | EP2540293A1 Increase in efficiency of the therapeutic effect of pharmacological active agent-realising medical device |
| 01/02/2013 | EP2540292A1 DHA and EPA in the reduction of oxidative stress |
| 01/02/2013 | EP2540291A1 Zinc oxide/acid containing compositions and methods for treating and/or preventing enzymatic irritation |
| 01/02/2013 | EP2540290A1 Adapalene for the long-term treatment of acne vulgaris |
| 01/02/2013 | EP2540289A1 Adhesive patch containing bisoprolol |
| 01/02/2013 | EP2540285A1 Capsule of complex danshen drop pill |
| 01/02/2013 | EP2540284A2 Compositions and methods for stabilized polysaccaride formulations |
| 01/02/2013 | EP2539857A2 Crystalline forms of the tri-mesylate salt of perphenazine-gaba and process of producing the same |
| 01/02/2013 | EP2539706A1 Arylpiperazone opioid receptor antagonists |
| 01/02/2013 | EP2539452A2 Treatment of pyrroline-5-carboxylate reductase 1 (pycr1) related diseases by inhibition of natural antisense transcript to pycr1 |
| 01/02/2013 | EP2539451A1 Compositions for targeted delivery of sirna |
| 01/02/2013 | EP2539389A1 Amine polymers for use as bile acid sequestrants |
| 01/02/2013 | EP2539357A2 Methods and compositions for the detection and treatment of cancer involving mirnas and mirna inhibitors and targets |
| 01/02/2013 | EP2539356A1 Modulation of smad3 expression |
| 01/02/2013 | EP2539348A1 Cephalosporin derivatives useful as -lactamase inhibitors and compositions and methods of use thereof |
| 01/02/2013 | EP2539347A2 Trimethoxyphenyl inhibitors of tyrosine kinase |
| 01/02/2013 | EP2539346A1 Heterocycloalkyl-containing thienopyrimidines for pharmaceutical compositions |
| 01/02/2013 | EP2539345A1 4 - [cycloalkyloxy (hetero) arylamino]thieno [2, 3 - d]pyrimidines having mnkl/ mnk2 inhibiting activity for pharmaceutical compositions |
| 01/02/2013 | EP2539344A1 Halogen or cyano substituted thieno [2,3-d]pyrimidines having mnk1/mnk2 inhibiting activity for pharmaceutical compositions |
| 01/02/2013 | EP2539343A1 Thienopyrimidines containing a substituted alkyl group for pharmaceutical compositions |
| 01/02/2013 | EP2539342A1 Pyrazolopyrimidine compounds and their use as pde10 inhibitors |
| 01/02/2013 | EP2539341A1 Derivatives of 1-phenyl-1,5-dihydro-benzo[b][1.4]diazepine-2.4-dione as inhibitors of hiv replication |
| 01/02/2013 | EP2539340A1 Pyrazolopyridazine derivatives for the treatment of hepatitis c |
| 01/02/2013 | EP2539339A2 10'-fluorinated vinca alkaloids provide enhanced biological activity against mdr cancer cells |
| 01/02/2013 | EP2539337A1 Pyrido[3,2-d]pyrimidine pi3k delta inhibitor compounds and methods of use |
| 01/02/2013 | EP2539333A1 Dimeric iap inhibitors |
| 01/02/2013 | EP2539328A1 Novel water soluble furoxan derivatives having antitumor activity |
| 01/02/2013 | EP2539327A1 Oxadiazole compounds, their preparation and use |
| 01/02/2013 | EP2539326A1 Bisaryl-bonded aryltriazolones and use thereof |
| 01/02/2013 | EP2539323A1 Compounds as bradykinin b1 antagonists |
| 01/02/2013 | EP2539322A1 Inhibitors of beta-secretase |
| 01/02/2013 | EP2539321A1 Saxagliptin intermediates, saxagliptin polymorphs, and processes for preparation thereof |
| 01/02/2013 | EP2539317A2 Dihydrolipoic acid derivatives comprising nitric oxide and therapeutic uses thereof |
| 01/02/2013 | EP2539313A2 Crystal forms of o-desmethylvenlafaxine fumarate |
| 01/02/2013 | EP2539312A1 Nutritional composition |
| 01/02/2013 | EP2539310A1 Synthesis of magnolol and its analogue compounds |
| 01/02/2013 | EP2538978A1 Use of ep4 receptor antagonists in the treatment of il-23 mediated diseases |
| 01/02/2013 | EP2538961A2 Methods for inhibiting necrosis |
| 01/02/2013 | EP2538960A1 Surfactant composition |
| 01/02/2013 | EP2538955A2 Pharmaceutical or neutraceutical formulation |
| 01/02/2013 | EP2538949A1 Silicon-containing biodegradable material for anti-inflammatory therapy |
| 01/02/2013 | EP2538948A1 Biodegradable material containing silicon, for pro-angiogenetic therapy |
| 01/02/2013 | EP2538947A1 Polyimidazoles for use as bile acid sequestrants |
| 01/02/2013 | EP2538946A1 Anti-viral formulations |
| 01/02/2013 | EP2538945A2 Oral b12 therapy |
| 01/02/2013 | EP2538944A2 Method for treating brain cancer |
| 01/02/2013 | EP2538943A1 Braf mutations conferring resistance to braf inhibitors |
| 01/02/2013 | EP2538942A1 Treatment of dermatological allergic conditions |
| 01/02/2013 | EP2538941A1 Pyrrolidine substituted flavones for the treatment of inflammatory disorders |
| 01/02/2013 | EP2538940A1 Diet and methods for improving learning capacity, mood and behavior in mammals |
| 01/02/2013 | EP2538939A1 Prevention and treatment of diseases caused by elevated levels of deoxy-sphingolipids |
| 01/02/2013 | EP2538938A1 Fungal nail treatment composition |
| 01/02/2013 | EP2538937A1 Combination of a centrally-acting analgesic and a selective cyclooxygenase - 2 inhibitor anti - inflammatory agent for the treatment of inflammation and pain in the veterinary field |
| 01/02/2013 | EP2538936A1 Nitisinone for treatment of oculocutaneous/ocular albinism and for increasing pigmentation |
| 01/02/2013 | EP2538935A2 Suppression of cancer growth and metastasis using nordihydroguaiaretic acid derivatives with 7-hydroxystaurosporine |
| 01/02/2013 | EP2538934A1 Method of accelerating corneal wound healing |
| 01/02/2013 | EP2538933A2 Use of essential oil of oregano or rosewood in the treatment of malign keratosis |
| 01/02/2013 | EP2538932A2 Use of essential oil of oregano or rosewood in the treatment of actinic keratosis |
| 01/02/2013 | EP2538931A1 Products and methods |